



(51) International Patent Classification:

A61K 31/395 (2006.01) A61K 31/454 (2006.01)

A61K 31/4184 (2006.01) A61P 31/12 (2006.01)

(21) International Application Number:

PCT/US2022/034083

(22) International Filing Date:

17 June 2022 (17.06.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/212,047 17 June 2021 (17.06.2021) US

(71) Applicant: ATEA PHARMACEUTICALS, INC.
[US/US]; 125 Summer Street, Boston, MA 02110 (US).

(72) Inventors: SOMMADOSSI, Jean-Pierre; c/o Atea Pharmaceuticals, Inc., 125 Summer Street, Boston, MA 02110 (US). MOUSSA, Adel; c/o Atea Pharmaceuticals, Inc., 125 Summer Street, Boston, MA 02110 (US). PIETROPALO, Keith, M.; c/o Atea Pharmaceuticals, Inc., 125 Summer Street, Boston, MA 02110 (US). ZHOU, Xiao-Jian; c/o Atea Pharmaceuticals, Inc., 125 Summer Street, Boston, MA 02110 (US).

(74) Agent: BELLOWS, Brent, R. et al.; Knowles Intellectual Property Strategies, LLC, 400 Perimeter Center Terrace, Suite 200, Atlanta, GA 30346 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ADVANTAGEOUS ANTI-HCV COMBINATION THERAPY

(57) Abstract: A synergistic pharmaceutical combination of Compound 1 or a pharmaceutically acceptable salt thereof (e.g., Compound 1-A) and Compound 2 or a pharmaceutically acceptable salt thereof, as well as its uses to treat hepatitis C or a condition related to hepatitis C, as well as methods for the manufacture of the pharmaceutical combination: 1, 1-A, 2






FIG. 33



Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*